US Markets Closed

AI-assisted · Not financial adviceNot advice

AI-assisted · Not financial advice.

US Markets Closed

AI-assisted · Not financial adviceNot advice

US Markets Closed

AI-assisted · Not financial adviceNot advice

$PFE

Name: PFE (Pfizer) — Market Sentiment & Discussion
Creator: MarketMind
License: https://stockmarketsentimentai.com/methodology

Pfizer· 10/11/2026, 5:21:42 PM

Three questions about PFE

Buy, wait, or sell today?: Data unavailable right now
Clean chart pattern?: Pattern confirmed — Pullback in uptrend
Passes the small-cap health check?: Not applicable — a large-cap index name, outside this screen

Analyst & Event Activity

Analyst Rating Changes

Oct 9JP MorganNeutral (reiterated)

Oct 8Cantor FitzgeraldNeutral (reiterated)

Oct 6ScotiabankSector Outperform (reiterated)

Reddit: MixedAttention: Watching

Community Take (7D)

Mixed feelings on Pfizer arise as dividend yield rises, with caution noted in comparisons. Exploration of acquisitions in the weight-loss market reported in the news may signal strategic growth.

The Story

News Summary

Pfizer explores acquisitions in weight-loss market

Key Events

Jul 2:Pfizer has the funds to acquire more companies. Buying Kailera Therapeutics would help Pfizer establish a stronger foothold in the weight-loss market.
Jun 29:Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide injection have passed a preliminary review for inclusion in China's basic medical insurance drug catalogue.
Jun 28:One of Pfizer's promising oncology candidates recently failed a phase 3 study. The drugmaker is also losing its CFO.

Sentiment: 70% bullish / 30% neutral (early) → 40% bearish / 40% cautious / 20% bullish (late)

Impact: Initial optimism about acquisitions and drug approvals shifted to concerns over failed trials and executive changes.

Risks: failed drug trials, executive turnover

Analyst ConsensusHold (39 analysts)

Target: $29 avg (+13% upside)

15 Buy · 23 Hold · 1 Sell

Signal

Divided

Confidence

65%

Based on curated news sources (not retail comments)

Over the last 7 days: Positive developments in drug approvals contrast with management changes and failed trials.

SentimentNeutral

AnalysisHype

Bullish Factors

✓Pfizer's GLP-1 drug Ecnoglutide passed preliminary review for inclusion in China's medical insurance drug catalogue.
✓Pfizer has the funds to acquire more companies, potentially strengthening its market position.

Risk Factors

✗A promising oncology candidate recently failed a phase 3 study.
✗Pfizer is losing its CFO, which may impact management stability.

Analyst target

13% upside · 4 analysts · $26–$33 range

▲ $29

Earnings

EPS: $2.97 → $2.90 (2026 vs 2027)

▼ Expected to decline 3%

Insiders (90d)

3 buys, 1 sell

Last: BUY Aug 12· 61d ago

▲Net buying $2.9M

Rules-based signal view →

Analyze with AI yahoo!finance Reddit Answers

AI-assisted · Not financial advice.

$PFE - Pfizer | MarketMind | MarketMind

$PFE

Pfizer· 10/11/2026, 5:21:42 PM

Three questions about PFE

Buy, wait, or sell today?: Data unavailable right now
Clean chart pattern?: Pattern confirmed — Pullback in uptrend
Passes the small-cap health check?: Not applicable — a large-cap index name, outside this screen

Analyst & Event Activity

Analyst Rating Changes

Oct 9JP MorganNeutral (reiterated)

Oct 8Cantor FitzgeraldNeutral (reiterated)

Oct 6ScotiabankSector Outperform (reiterated)

Options positioning: Neutral — More betting on upside (1.4× more call than put volume today). Unusual bets on $28 downside — 1.0× normal activity. analysts: 16 buy vs 1 sell.

Reddit: MixedAttention: Watching

Community Take (7D)

Mixed feelings on Pfizer arise as dividend yield rises, with caution noted in comparisons. Exploration of acquisitions in the weight-loss market reported in the news may signal strategic growth.

The Story

News Summary

Pfizer explores acquisitions in weight-loss market

Key Events

Jul 2:Pfizer has the funds to acquire more companies. Buying Kailera Therapeutics would help Pfizer establish a stronger foothold in the weight-loss market.
Jun 29:Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide injection have passed a preliminary review for inclusion in China's basic medical insurance drug catalogue.
Jun 28:One of Pfizer's promising oncology candidates recently failed a phase 3 study. The drugmaker is also losing its CFO.

Sentiment: 70% bullish / 30% neutral (early) → 40% bearish / 40% cautious / 20% bullish (late)

Impact: Initial optimism about acquisitions and drug approvals shifted to concerns over failed trials and executive changes.

Risks: failed drug trials, executive turnover

Analyst ConsensusHold (39 analysts)

Target: $29 avg (+13% upside)

15 Buy · 23 Hold · 1 Sell

Signal

Divided

Confidence

65%

Based on curated news sources (not retail comments)

Over the last 7 days: Positive developments in drug approvals contrast with management changes and failed trials.

SentimentNeutral

AnalysisHype

Bullish Factors

✓Pfizer's GLP-1 drug Ecnoglutide passed preliminary review for inclusion in China's medical insurance drug catalogue.
✓Pfizer has the funds to acquire more companies, potentially strengthening its market position.

Risk Factors

✗A promising oncology candidate recently failed a phase 3 study.
✗Pfizer is losing its CFO, which may impact management stability.

Analyst target

13% upside · 4 analysts · $26–$33 range

▲ $29

Earnings

EPS: $2.97 → $2.90 (2026 vs 2027)

▼ Expected to decline 3%

Insiders (90d)

3 buys, 1 sell

Last: BUY Aug 12· 61d ago

▲Net buying $2.9M

Rules-based signal view →

Analyze with AI yahoo!finance Reddit Answers